These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37461956)

  • 1. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Sands B; Pondel M; Silver M; Petersen A; Wolf D; Panaccione R; Loftus E; Colombel JF; Sturm A; D'Haens G
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S8. PubMed ID: 37461950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
    N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozanimod: A Review in Ulcerative Colitis.
    Paik J
    Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
    Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG
    Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
    Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
    J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
    Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M
    J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
    Aoun R; Hanauer S
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.